ABOS Stock Summary and Trading Ideas (Acumen Pharmaceuticals | NASDAQ:ABOS)

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Acumen Pharmaceuticals trades on the NASDAQ stock market under the symbol ABOS.

As of April 23, 2024, ABOS stock price climbed to $3.20 with 125,553 million shares trading.

ABOS has a beta of 2.57, meaning it tends to be more sensitive to market movements. ABOS has a correlation of 0.12 to the broad based SPY ETF.

ABOS has a market cap of $192.26 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that ABOS belongs to (by Net Assets): VTI, VXF, IWC, AVSC, DFAS.

ABOS has underperformed the market in the last year with a price return of -20.0% while the SPY ETF gained +24.2%. ABOS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.6% and -17.7%, respectively, while the SPY returned +4.9% and -2.6%, respectively.

ABOS support price is $3.00 and resistance is $3.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABOS stock will trade within this expected range on the day.